Aspirin Challenge

Phase 1Small molecule

RRush University Medical Center

Aspirin Challenge is one of 47 small molecule programs targeting Liver Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseActive, not recruiting

Liver DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 3

—2

Viagra

VViatris Specialty LLC

Phase 3

1 3

Inderal

WWyeth-Lederle Vaccines

Phase 3

1 4

Neurontin

VViatris Specialty LLC

Phase 3

1 5

Sandostatin

Sun Pharma

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Promacta

3 8

Retatrutide

Ozempic

1 10

Jardiance

Boehringer Ingelheim

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Disease1 trial

Alcohol, Gut Leakiness, & Liver Disease

Completed·RRush University Medical Center·Phase 1·NCT05428072·195 enrolled

Unspecified1 trial

Mechanisms of Dupilumab in AERD

Recruiting·SScripps Clinic·Phase 2·NCT05031455·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Aspirin Challenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aspirin Challenge compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aspirin Challenge. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rush University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRush University Medical Center

Aspirin Challenge

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Liver Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News